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ABSTRACT: MicroRNAs (miRNAs) are known to be
important post-transcription regulators of gene expression.
Aberrant miRNA expression is associated with pathological
disease processes, including carcinogenesis. Therefore, miR-
NAs are considered significant therapeutic targets for cancer
therapy. MiRNAs do not act alone, but exhibit their functions
by forming RNA-induced silencing complex (RISC). Thus, the
regulation of RISC activity is a promising approach for cancer
therapy. MiRNA is a core component of RISC and is an
essential to RISC for recognizing target mRNA. Thereby, it is expected that development of the method to promote the release
of miRNA from RISC would be an effective approach for inhibition of RISC activity. In this study, we synthesized novel peptide-
conjugated oligonucleotides (RINDA-as) to promote the release of miRNA from RISC. RINDA-as showed a high rate of miRNA
release from RISC and high level of inhibitory effect on RISC activity.
■ INTRODUCTION
MicroRNAs (miRNAs) are a type of noncoding RNA that
induce post-transcriptional gene silencing of their target genes
and regulate a wide range of biological processes, including
apoptosis, differentiation, metabolism, and cell proliferation.1−6
According to recent reports, the aberrant expression of
miRNAs is associated with most pathological disease processes,
including carcinogenesis.7−12 In fact, a vast number of studies
have reported that miRNA expression is significantly different
between normal and tumor cells in humans.13 Therefore,
miRNAs are considered significant therapeutic targets for
cancer therapy.
The primary transcripts of miRNA genes are transcribed in
the nucleus.14 The precursor miRNAs are exported and
processed to an approximately 22-nucleotide miRNA du-
plex15,16 by some enzymes, such as Drosha, Exportin-5, and
Dicer.17−19 The miRNA duplex is loaded into Argonaute
protein (Ago) and rapidly unwound in a ribonucleoprotein
complex called RNA-induced silencing complex (RISC).20−23
During this process, one strand of the miRNA duplex is
retained in RISC, while the other strand is released from
Ago.20,24 MiRNAs do not act alone but exhibit their function by
forming RISC. Therefore, to regulate miRNA functions, RISC
activity must be controlled.
The most conventional approach for the inhibition of RISC
functions is an antisense oligonucleotide (ASO) with the
complementary sequence of the miRNA in RISC.25−27 In fact,
several studies have demonstrated the effectiveness of ASO as
an anticancer drug targeting miRNA.28 ASOs have been
optimized for increased binding affinity, improved nuclease
resistance, and in vivo delivery. To achieve the purpose, a
variety of chemical modifications of ASO have been developed,
including modifications of the nucleobase, the sugar, and the
internucleotide linkages.29 These modifications have improved
the inhibitory effects of ASO on miRNA functions and have
been adapted for nucleic acid drugs.28,29 For instance, an
miRNA inhibitor termed “Miravirsen”, which is a β-D-oxy-
locked nucleic acid-modified phosphorothioate antisense
oligonucleotide targeting the liver-specific miRNA-122 (miR-
122), has demonstrated broad antiviral activity and has shown
promising results in phase II clinical trials.30,31 Now, ASOs are
considered promising molecules for the regulation of RISC
functions; therefore, ASOs should be improved further as with
other regulation pathways for miRNA. The purpose of this
Received: September 15, 2015
Revised: October 14, 2015
Published: October 16, 2015
Article
pubs.acs.org/bc
© 2015 American Chemical Society 2454 DOI: 10.1021/acs.bioconjchem.5b00501
Bioconjugate Chem. 2015, 26, 2454−2460
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
study was to develop novel ASOs to further improve their
inhibitory effects on RISC functions.
Recently, MacRae and co-workers reported interesting
phenomena in which highly complementary wild-type RNA
significantly accelerates the release of miRNA from Ago in
RISC.32 MiRNA is a core component of RISC and essential to
RISC for recognizing target mRNAs and regulating gene
expression. From these findings, we expected that the
development of a method to promote the release of miRNA
from RISC would be an effective approach for inhibition of
RISC activity. In the present study, we intended to increase the
inhibitory effects of ASO on RISC activity by releasing miRNA
from RISC. Here we designed an antagonistic peptide called
“RINDA” (RISC-inhibitor disturbing active-site of RISC) to
promote the release of miRNA from RISC and synthesized
novel peptide-conjugated oligonucleotides (RINDA-as). In this
paper, the applicability of the RINDA-as to inhibit RISC
functions is presented and interesting findings are disclosed.
■ RESULTS AND DISCUSSION
Design and Synthesis of Peptide-Conjugated Oligo-
nucleotides. Among the proteins of the RISC components,
Argonaute2 protein (Ago2) is an essential component of RISC
for the cleavage of specific target mRNA. The Ago2 family has a
highly conserved basic motif called PIWI-box. The phosphory-
lated 5′-end of miRNA is anchored in the PIWI-box and
interacts with the lysine residues of the PIWI-box. The
mutations of the Lys that interact with the 5′-phosphate of
miRNA in the PIWI-box resulted in an attenuated holding
ability of miRNA in Ago2.33,34 Therefore, by disturbing the
interaction between the PIWI-box and 5′-end of miRNA, it is
expected that the release of miRNA from Ago2 would be
induced. We designed an antagonist called “RINDA” (RISC-
inhibitor disturbing active site of RISC) to disturb the
interaction between the PIWI-box and 5′-end phosphate of
miRNA (Figure 1A). For this purpose, we selected two kinds of
peptides as RINDA. To interact with 5′-phosphate of miRNA
entrapped in cationic PIWI-box, a lysine trimer was designed as
RINDA(K3) to mimic the interaction between the 5′-
phosphate of miRNA and PIWI-box. On the other hand, to
interact with the lysine residues in PIWI-box interacting 5′-
phosphate of miRNA, a glutamic acid trimer was also designed
as RINDA(E3). According to a simulation of spatial structure
by MacroModel, we predicted that the length of the peptide
would need to be at least 3 residues long to reach the PIWI-
box.
We conjugated RINDA peptides to the 3′-end of ASOs
targeting miRNA (Figure 1B). These oligonucleotides have the
2′-O,4′-C-ethylene-bridged nucleosides (ENA) in the sequen-
ces.35,36 Oligonucleotides containing ENA show very high
affinity toward their complementary RNA and have higher
nuclease resistance than that of wild-type RNA. Therefore, we
selected ENA as modification on RINDA-as.
As the target of ASOs, miRNA targeting firefly luciferase
mRNA (mir-Luc) was selected. The synthesis of RINDA-
conjugated oligonucleotide (RINDA-as) was conducted by a
combination of Fmoc solid-phase chemistry and the phosphor-
amidite method on 3′-Amino-Modifier CPG (GLEN RE-
SERCH) (Figure S1). First, we evaluated the thermodynamic
stability of duplexes between RINDA-as and the miRNA of mir-
Luc. The results are summarized in Figure 1B. The Tm values of
the duplex between RINDA-as and miRNA were approximately
equal to those of ASO. These results indicate that RINDA did
not affect the thermodynamic stability of the ASO-miRNA
duplex.
RINDA(E3)-as Promoted the Release of miRNA from
RISC. Next, we evaluated the effects of RINDA-as on the
release of miRNA from RISC by the unloading assay. For this
Figure 1. (A) Schematic illustrations of release of miRNA from RISC by using RINDA-as. (B) Sequences of antisense oligonucleotides.
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experiment, we prepared immobilized RISC magnetic beads as
described in Materials and Methods (Figure 2A). The
dissociation ratio of miRNA from RISC was evaluated by
measuring the radioactivity (Figure 2B). Surprisingly, we found
that miRNA was released from RISC in a time-dependent
manner using ASO, which did not have any peptides on the 3′-
end. As described in the Introduction, MacRae’s group revealed
that highly complementary wild-type RNA significantly
accelerates the release of miRNA from Ago in RISC;32
however, there is no report to elucidate whether the release
of miRNA from RISC is induced by binding to chemical-
modified ASOs which do not accept cleavage by RISC. To the
best of our knowledge, our result is the first example that the
chemically modified ASOs induce the release of miRNA from
RISC and suggests the presence of the inhibitory pathway in
RISC activity by releasing miRNA form RISC using ASO. We
think this finding will bring a new mechanistic interpretation of
the function of ASO targeting miRNA.
Furthermore, we also found that the releasing effect was
enhanced in the case of RINDA(E3)-as. In contrast, in the case
of RINDA(K3)-as, the ratio of released miRNA from RISC was
lower than in the case of ASO. In the case of control ASO (ctrl
ASO), whose sequence was not complementary to the miRNA
of mir-Luc, the release of miRNA was not observed. These
results show that miRNA is released from RISC by binding to
ASO, and an anionic peptide promotes the releasing effect of
miRNA by ASO.
In the case of RINDA(K3)-as, the amount of released
miRNA from RISC was the lowest compared with that of other
oligonucleotides. At first, we expected that RINDA(K3)-as
would interact with the 5′-phosphate of miRNA anchored in
the PIWI-box and enhance the release of miRNA from RISC.
However, contrary to our expectations, the amount of released
miRNA from RISC was the lowest among the case of other
oligonucleotides. For this reason, we speculate that the
electrostatic repulsion between RINDA(K3) and basic amino
acid residues in the PIWI-box might not be conducive to
RINDA(K3)-as entering the PIWI-box in RISC.
In contrast, in the case of RINDA(E3)-as, the ratio of
released miRNA was the highest compared with that of other
oligonucleotides. These results suggest that the interaction
between the lysine residues in the PIWI-box and RINDA(E3) is
important for the release of miRNA from RISC. This result also
has implications for design of ASOs targeting miRNA. The
conventional ASOs can act as sequence specific inhibitors of
miRNA function and RINDA(E3)-as can promote the releasing
effect of miRNA from RISC, which might be more effective
than the conventional ASOs.
To evaluate the effect of the number of glutamic acid
residues in RINDA-as on the release of miRNA from RISC, we
Figure 2. (A) Schematic illustrations of the unloading assay. Ago2 was immobilized on Protein G Magnetic beads using anti-Ago2 antibody. After
the unloading reaction, the beads were washed and the supernatant were isolated from the beads. The dissociation ratio of miRNA from RISC was
evaluated by measuring the radioactivity. (B) Time course analysis of the percent of released miRNA from RISC. RISC on beads = 10 fmol.
[RINDA-as] = [ASO] = [Ctrl ASO] = 1 μM. In the case of RINDA(E3)-as, it was found that the rate of released miRNA from RISC was faster than
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synthesized a series of RINDA(En)-as, RINDA(E1)-as, to
RINDA(E6)-as (Figure 1B). The results are shown in Figure 3.
The ratio of released miRNA proportionally increased to the
number of glutamic acids in RINDA-as, and the released ratio
showed a maximum at RINDA(E3)-as, which has three
glutamic acid residues, suggesting that the ratio of released
miRNA was the highest when using RINDA(E3). From the
above findings, it is suggested that the optimal length of
RINDA(En) to interact with the lysine residues in the PIWI-
box is three.
To examine whether the releasing effect is enhancing by
anionic moieties of RINDA-as or not, we prepared a 23-mer
antisense oligonucleotide (ASO-23) with the same negative
charges as RINDA(E3)-as in their phosphate groups. Then, we
evaluated the ratio of released miRNA from RISC when using
ASO-23 (Figure 4). In the case of ASO-23, the ratio of released
miRNA from RISC was almost equal to that of ASO but lower
than that of RINDA(E3)-as. This observation indicates that the
number of anionic moieties in the phosphate groups of an
oligonucleotide is not important for enhancing the release of
miRNA from RISC; however, the structure of glutamic acids
has some essential factors for interacting with basic amino acid
residues in the PIWI-box.
Furthermore, it was also found that the dissociation ratio of
miRNA from RISC is plateauing at ∼40% in either case. We
also evaluated the releasing effect of miRNA from RISC by
oligonucleotides for a prolonged time (∼24 h) and found that
the experimental results did not change (data not shown).
Therefore, the reaction is certainly equilibrated at 1 h. We used
an excess of antisense oligonucleotides (ASO) in either case, so
the above results suggest that about 60% of RISC did not
release the miRNA by binding to ASO. These findings indicate
that there are several kinds of RISC complexes and their
miRNA-holding abilities in RISC are different depending on
the complex formation of RISC. It is known that RISC is
composed of Argonaute−miRNA complex which is a core
component of RISC, and subcomponent proteins including
Dicer, TRBP, and TRNC6A/GW182.37,38 RISC exhibits its
various functions by associating such proteins and it is
predicted that the functions of RISC are different on the
complex of RISC. We speculate that the difference of the ability
to hold miRNA in RISC is attributed to subcomponents of
RISC.
Release of miRNA from RISC Is Effective for the
Inhibition of RISC Activity. As mentioned above, the release
of miRNA using ASO was enhanced by the conjugation of
RINDA(E3). To investigate the relationship between the
releasing and inhibitory effects on RISC activity, we evaluated
the inhibitory effects of RINDA-as on RISC function in HeLa
Figure 3. Percent of the released miRNA from RISC by RINDA(En)-
as. RISC on beads = 10 fmol. [RINDA-as] = [ASO] = [Ctrl ASO] = 1
μM. PK-treated group: Proteinase K treated group. RINDA(E3)-as
showed the highest ratio of released miRNA from RISC than that of
the other RINDA-as.
Figure 4. Time course analysis of the percent of released miRNA from RISC. In the case of ASO-23, the rate of released miRNA from RISC was
equal to that of ASO, but lower than the case of RINDA(E3)-as. From these results, the number of anionic moieties in the phosphate groups of an
oligonucleotide is not important for enhancing the release of miRNA from RISC. RISC on beads = 10 fmol. [RINDA-as] = [ASO] = [ASO-23] =
[Ctrl ASO] = 1 μM.
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cells. As a target of RINDA-as, luciferase mRNA was selected.
In this system, luminescence intensity of firefly luciferase is
already down-regulated by RISC derived from anti-luciferase
miRNA. If RINDA-as inhibits the RISC function, it is expected
that luminescence intensity would be recovered. The results are
shown in Figure 5. Luminescence intensity was substantially
recovered in the case of ASO and RINDA(E3)-as. In particular,
the luminescence intensity of RINDA(E3)-as-treated cells was
greater (+10−20%) than that of ASO-treated cells. These
results show that the inhibitory effect on the RISC activity of
RINDA(E3)-as is higher than that of ASO. On the other hand,
the luminescence intensity of RINDA(K3)-as treated cells was
down-regulated (−30−40%) compared with that of ASO-
treated cells, suggesting that the inhibitory effect of RINDA-
(K3)-as was lower than that of ASO. Good relationships
between inhibitory effects on the RISC activity and release of
miRNA from RISC were observed. Taking these results into
consideration, enhancing the release of miRNA from RISC is a
promising way for inhibition of RISC activity.
■ CONCLUSIONS
In this study, we successfully demonstrated the specific
regulation of RISC activity using RINDA-as. We found that
ASO, which did not have any peptides, induced the release of
miRNA from RISC. This significant finding implies new
mechanisms for inhibition of RISC activity. Furthermore, we
succeeded in enhancing the release of miRNA from RISC and
the inhibitory effects on RISC activity by conjugating
RINDA(E3) to the 3′-end of ASO. These observations suggest
that our strategy for inhibition of RISC activity will be a
promising method for controlling miRNA activity in cancer
cells. The details of the inhibitory mechanisms of RINDA(E3)-
as on the RISC activity are still being unveiled. To investigate
the details of the underlying mechanisms of the releasing effect
introduced by RINDA(E3)-as, we will try to prepare several
kinds of RINDA-as that have other peptide sequences or other
anionic moieties and will consider the effect of peptide
sequence on the releasing effect. Furthermore, in the near
future, we will try to investigate X-ray crystallography as a
means to reveal the mechanisms of the releasing effect on the
RISC activity.
■ MATERIALS AND METHODS
Oligonucleotide Preparation. Each RINDA-as was
synthesized by phosphoramidite chemistry and solid-phase
peptide synthesis. The controlled-pore glass supports were
treated with 0.4 M NaOH and 80% methanol at 55 °C for 8 h.
RINDA-as was purified by RP-HPLC on a CAPCELL PAK C-
18 column (4.6 Å 150 mm, Shiseido, Co. Ltd., Tokyo, Japan)
with a linear gradient of acetonitrile in 0.1 M triethylammo-
nium acetate (TEAA, pH 7.0) at a flow rate of 0.8 mL min−1
(acetonitrile gradient: 0−50% for 50 min). The purity of each
oligonucleotide is shown in Figure S2. The mass spectra of each
oligonucleotide purified by RP-HPLC were obtained using ESI-
MS (Bruker Daltonics K.K., Bremen, Germany). These data are
shown in Figure S2.
Measurements of UV-Melting Profiles of Duplexes of
RINDA-as with the miRNA of mir-Luc. UV melting profiles
of the duplex between RINDA-as and the miRNA of mir-Luc
were obtained by a UV spectrophotometer equipped with a
programmed thermal controller at an increase rate of 1.0 °C/
min. The sample solutions were prepared in 10 mM phosphate
buffer (pH 7.0) containing 0.1 M NaCl, and the concentration
of oligonucleotides was fixed at 1.0 μM.
Luciferase Reporter Assays. HeLa cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) FBS, 100 units per mL penicillin, and 100 μg/
mL streptomycin at 37 °C in 5% CO2. The cells were plated
onto 96-well plates (32 mm2/well) at a density of 4.5 × 104
cells/mL in an antibiotic-free medium, transfected, and
harvested for 24 h. On the next day, cells were transfected
with 20 nM of mir-Luc using Lipofectamine RNAiMAX
(GIBCO, CA, United States) according to the manufacturer’s
protocol. On the following day, the cells were cotransfected
with pGL4.13 (0.1 μg/well) and pGL4.73 (0.25 μg/well)
plasmids and ASOs using Lipofectamine 2000 (GIBCO). After
24 h incubation, the cells were lysed and the luminescence
activity of lysate was measured with a Dual Luciferase assay kit
(Promega, WI, United States).
In Vitro Unloading Assays. Immobilizing RISC on Beads.
HEK293T cell lysate expressing hAgo2 was prepared, according
to a published method. For RISC assembly, 4 μL of the cell
lysate was added to 3 μL of 40 × reaction mix, and 2 μL of mir-
Luc duplex (32P-labeled, stock concentration 100 nM), and
incubated at 37 °C for 30 min. After incubation, the reaction
mix was added to 2 μL anti-hAgo2 antibody and stirred at 4 °C
for 30 min. Then, 12 μL reaction mix was added to 20 μL
Dynabeads Protein G for immunoprecipitation (Thermo Fisher
Scientific Inc., MA, United States) and stirred at 4 °C for 2 h.
To remove unbound material, the beads were washed with a
washing buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2
mM MgCl2, 0.5 mM TCEP).
Unloading Assay. For this assay, 20 μL RISC-bound beads
was suspended in a 1.5 mL centrifuge tube, and was
preincubated at 37 °C for 5 min. The unloading reaction was
initiated by the addition of 1 μM (final concentration) of
antisense oligonucleotide and incubation at 37 °C. After the
incubation, the beads were isolated and the supernatant was
carefully removed as the “unloaded miRNA” fraction. The
beads were washed immediately with 40 μL washing buffer (20
mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl2, 0.5 mM
TCEP) to remove any supernatant. The washed beads were
saved as the “RISC (including miRNA)” fraction. The
radioactivity of each fraction was measured using a radiation
Figure 5. Inhibitory effects of RINDA-as on RISC function in HeLa
cell. HeLa cells were transfected with 20 nM mir-Luc duplex. The
luminescence intensity of RINDA(E3)-as-treated cells was greater than
that of ASO. On the other hand, the luminescence intensity of
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analyzer. The dissociation ratio of miRNA from RISC was
evaluated by measuring the radioactivity.
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